Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region☆

[1]  J. Dillner,et al.  Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial , 2015, International journal of cancer.

[2]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[3]  J. Dillner,et al.  Are 20 human papillomavirus types causing cervical cancer? , 2014, The Journal of pathology.

[4]  T. Weiss,et al.  Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). , 2014, Cancer epidemiology.

[5]  E. Unger,et al.  HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[6]  C. Wheeler,et al.  Human Papillomavirus Genotype-Specific Prevalence across the Continuum of Cervical Neoplasia and Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[7]  Jack Cuzick,et al.  Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[8]  E. Unger,et al.  Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009 , 2014, Cancer Causes & Control.

[9]  Maria Hortlund,et al.  Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance , 2014, PloS one.

[10]  P. Castle,et al.  Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. , 2013, The Journal of infectious diseases.

[11]  T. Weiss,et al.  Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease , 2012, Infectious Agents and Cancer.

[12]  E. Unger,et al.  The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions , 2012, Cancer Causes & Control.

[13]  D. Gertig,et al.  Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact , 2011, Expert review of anti-infective therapy.

[14]  N. Muñoz,et al.  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.

[15]  C. Wheeler,et al.  Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[16]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[17]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[18]  S. Wacholder,et al.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants , 2009, International journal of cancer.

[19]  N. Muñoz,et al.  Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.

[20]  M. Madeleine,et al.  A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[21]  S. Goldie,et al.  Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications , 2008, Reproductive health matters.

[22]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[23]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[24]  Diane Solomon,et al.  The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. , 2007, American journal of clinical pathology.

[25]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[26]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[27]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[28]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[29]  B. Hankey,et al.  Surveillance, Epidemiology, and End Results Program , 1999 .